<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956836</url>
  </required_header>
  <id_info>
    <org_study_id>HUVirgenRocio</org_study_id>
    <nct_id>NCT03956836</nct_id>
  </id_info>
  <brief_title>Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)</brief_title>
  <acronym>HIPEC-COAG</acronym>
  <official_title>Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytoreductive surgery (CRC) with intraperitoneal hyperthermal chemotherapy (HIPEC) has been
      shown to improve survival in selected patients with peritoneal carcinomatosis. 51% of
      patients are transfused due to the high intraoperative blood loss caused by surgery and the
      appearance of a perioperative coagulopathy attributed to the loss of proteins into the
      peritoneal cavity, the high fluid turnover and possibly the action of hyperthermic
      chemotherapy. So far, the haemostatic changes described consist of a decrease in the levels
      of antithrombin III and the platelet count, as well as in alterations of the usual
      coagulation tests. Conventional coagulation tests analyze only the plasmatic phase of
      coagulation while viscoelastic tests, such as rotational thromboelastometry (ROTEM),
      reproduce the global coagulation process much more faithfully, keeping good correlation with
      perioperative bleeding.

      Objetive:

      The platelet, coagulation, von Willebrand and Factor XIII levels and function have not been
      consistently investigate in pre-established (fix) time periods in patients undergoing
      elective CRC with hyperthermia. This prospective observational study aimed at investigating
      the variations of the values of estándar coagulation test, ROTEM parameters, platelet
      function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and
      after 4h and 48 after surgery in 40 patients undergoing CRC. A control group (N=40 blood
      donors) will be also obtained by baseline comparasion and to obtain local reference ranges.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study aimed at investigating the variations of the values of
      estándar coagulation test, ROTEM parameters, platelet function assay (PFA-100), von
      Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in
      40 patients undergoing CRC. A control group (N=40 blood donors) will be also obtained by
      baseline comparasion and to obtain local reference ranges.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>Variations of CT-ROTEM</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in clotting time of ROTEM from baseline (preoperative) to 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of MCF-ROTEM</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in maximum clotting firmness of ROTEM 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of PFA-100</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in COL-EPI (platelet function) from of 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of Factor XIII</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in factor XIII Concentration of clotting factor from baseline (preoperative) of 48 hours post surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of von Willebrand</measure>
    <time_frame>48 hours</time_frame>
    <description>variations in von Willebrand Concentration from 48 hours post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion of red blood cells</measure>
    <time_frame>20 days</time_frame>
    <description>number of packed red blood cells and percentage of transfused patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coagulation Disorder</condition>
  <condition>Carcinomatosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII</intervention_name>
    <description>ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC</description>
    <other_name>ROTEM, PFA-100</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis of peritoneal surface malignancy of the ovarian and/or colo
        origin undergoing complete cytoreductive surgery (zero) combined with Hyperthermic
        Intraperitoneal Chemotherapy (HIPEC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Consecutive patients with peritoneal surface malignancy treated with cytoreductive
             surgery and HIPEC in the Department of Surgery of Virgen del Rocio General Hospital

          2. -All patients gave written informed consent.

          3. -Age above 18 years and Karnofsky performance status scale 450%

        Exclusion Criteria:

          1. - Exclusion criteria: were severe cardiovascular or respiratory disease,

          2. - Lower hemoglobin than 10,0 g/dL , platelet count 100,000/mm3,

          3. - Renal or hepatic failure,

          4. - Pregnancy,

          5. - Multiple partial intestinal obstruction or extensive involvement of the surface of
             the small bowel as well as distant and non-resectable metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio M Puppo Moreno, 1980</last_name>
    <phone>+34669410840</phone>
    <email>apuppo@telefonica.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio M Puppo Moreno, 1980</last_name>
      <phone>+34669410840</phone>
      <phone_ext>M</phone_ext>
      <email>apuppo@telefonica.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Antonio M. Puppo Moreno</investigator_full_name>
    <investigator_title>Critical Care Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

